Transgenic animals as drug factories: A new source of recombinant protein therapeutics

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The utility of transgenic animal bioreactors for the production of complex therapeutic proteins is based on lower production costs, higher production capacities and safer, pathogen free products. Until gene therapy becomes broadly efficacious, transgenic-derived therapeutics are the most attractive alternative for prophylactic, replacement therapy in genetic disorders, such as haemophilia. Many other disease states need short-term treatment of significant amounts of recombinant proteins that could be made amply available from transgenic animal sources. In addition, transgenic animals will provide an ideal expression system for the production of a portfolio of alternative therapeutics for patient populations developing inhibiting antibodies, for enhanced bioactivity, or for increased plasma clearance times. The FDA approval of a transgenic-derived therapeutic is still pending, but a review of Phase I and II data from antithrombin III from goat milk is encouraging, and companies are continuing to add potential therapeutics to their product pipeline.

Original languageEnglish (US)
Pages (from-to)1683-1690
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume7
Issue number10
DOIs
StatePublished - Oct 14 1998

Fingerprint

Genetically Modified Animals
Recombinant Proteins
Pharmaceutical Preparations
Therapeutics
Inborn Genetic Diseases
Antithrombin III
Hemophilia A
Bioreactors
Goats
Genetic Therapy
Milk
Costs and Cost Analysis
Antibodies
Population

Keywords

  • Recombinant DNA
  • Therapeutic
  • Transgenic livestock

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Transgenic animals as drug factories : A new source of recombinant protein therapeutics. / Van Cott, K. E.; Velander, W. H.

In: Expert Opinion on Investigational Drugs, Vol. 7, No. 10, 14.10.1998, p. 1683-1690.

Research output: Contribution to journalReview article

@article{81b66e01e5214d5da7e47b1a110db4dd,
title = "Transgenic animals as drug factories: A new source of recombinant protein therapeutics",
abstract = "The utility of transgenic animal bioreactors for the production of complex therapeutic proteins is based on lower production costs, higher production capacities and safer, pathogen free products. Until gene therapy becomes broadly efficacious, transgenic-derived therapeutics are the most attractive alternative for prophylactic, replacement therapy in genetic disorders, such as haemophilia. Many other disease states need short-term treatment of significant amounts of recombinant proteins that could be made amply available from transgenic animal sources. In addition, transgenic animals will provide an ideal expression system for the production of a portfolio of alternative therapeutics for patient populations developing inhibiting antibodies, for enhanced bioactivity, or for increased plasma clearance times. The FDA approval of a transgenic-derived therapeutic is still pending, but a review of Phase I and II data from antithrombin III from goat milk is encouraging, and companies are continuing to add potential therapeutics to their product pipeline.",
keywords = "Recombinant DNA, Therapeutic, Transgenic livestock",
author = "{Van Cott}, {K. E.} and Velander, {W. H.}",
year = "1998",
month = "10",
day = "14",
doi = "10.1517/13543784.7.10.1683",
language = "English (US)",
volume = "7",
pages = "1683--1690",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
number = "10",

}

TY - JOUR

T1 - Transgenic animals as drug factories

T2 - A new source of recombinant protein therapeutics

AU - Van Cott, K. E.

AU - Velander, W. H.

PY - 1998/10/14

Y1 - 1998/10/14

N2 - The utility of transgenic animal bioreactors for the production of complex therapeutic proteins is based on lower production costs, higher production capacities and safer, pathogen free products. Until gene therapy becomes broadly efficacious, transgenic-derived therapeutics are the most attractive alternative for prophylactic, replacement therapy in genetic disorders, such as haemophilia. Many other disease states need short-term treatment of significant amounts of recombinant proteins that could be made amply available from transgenic animal sources. In addition, transgenic animals will provide an ideal expression system for the production of a portfolio of alternative therapeutics for patient populations developing inhibiting antibodies, for enhanced bioactivity, or for increased plasma clearance times. The FDA approval of a transgenic-derived therapeutic is still pending, but a review of Phase I and II data from antithrombin III from goat milk is encouraging, and companies are continuing to add potential therapeutics to their product pipeline.

AB - The utility of transgenic animal bioreactors for the production of complex therapeutic proteins is based on lower production costs, higher production capacities and safer, pathogen free products. Until gene therapy becomes broadly efficacious, transgenic-derived therapeutics are the most attractive alternative for prophylactic, replacement therapy in genetic disorders, such as haemophilia. Many other disease states need short-term treatment of significant amounts of recombinant proteins that could be made amply available from transgenic animal sources. In addition, transgenic animals will provide an ideal expression system for the production of a portfolio of alternative therapeutics for patient populations developing inhibiting antibodies, for enhanced bioactivity, or for increased plasma clearance times. The FDA approval of a transgenic-derived therapeutic is still pending, but a review of Phase I and II data from antithrombin III from goat milk is encouraging, and companies are continuing to add potential therapeutics to their product pipeline.

KW - Recombinant DNA

KW - Therapeutic

KW - Transgenic livestock

UR - http://www.scopus.com/inward/record.url?scp=0031679794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031679794&partnerID=8YFLogxK

U2 - 10.1517/13543784.7.10.1683

DO - 10.1517/13543784.7.10.1683

M3 - Review article

C2 - 15991910

AN - SCOPUS:0031679794

VL - 7

SP - 1683

EP - 1690

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -